Introduction
============

Asthma is a common chronic respiratory tract disease in children, and it affects more than 6.1 million American children in recent years ([@b1-mmr-18-02-2153]). Minority and low-income children were reported that suffered from a higher ratio of asthma morbidity and mortality ([@b2-mmr-18-02-2153]). Asthma is characterized by allergy, recurring airway obstruction, and bronchospasm ([@b3-mmr-18-02-2153]). It is mainly caused by a combination of genetic and environmental factors, such as air pollution, allergens, viral infection, aspirin and beta blockers ([@b4-mmr-18-02-2153]). Although great scientific advances have improved our understanding of asthma and promoted abilities to control asthma effectively, the mechanism of asthma is still unclear and needs to be explored. Exploring the progressive of asthma and assessing asthma severity, especially asthma in children, have been defined as urgent and persistent task to initiating appropriate therapy.

Recent studies on asthma in children have focused on genetic factors, especially critical genes and mRNAs in the pathogenesis of childhood asthma ([@b5-mmr-18-02-2153]). β2-AR agonist is now the most important bronchodilator for the treatment of asthma in clinical, and the polymorphism of the *ADRB2* response to inhaled beta-agonists in children with asthma ([@b6-mmr-18-02-2153]). Besides, imbalance of CD4+ T cell subgroup were also major factors resulting in asthma, and study showed that differentiation of Th2 cell, regulatory T cells (Treg) were involved in the occurrence of asthma ([@b7-mmr-18-02-2153]). To date, the pathogenetic basis for the relationship between potential gene expression changes and asthma has not been clearly elucidated.

In 2017, Yang *et al* ([@b8-mmr-18-02-2153]) identified the DNA methylation and gene expression changes in nasal-epithelium (NE) tissue associated with childhood asthma. They demonstrated that the methylation marks in the nasal epithelia of children with allergic asthma were associated with gene expression changes. Based on the microarray data deposited by Yang *et al* ([@b8-mmr-18-02-2153]), as well as other three microarray data of asthma downloaded from GEO database, we identified many differentially expressed genes (DEGs) from different tissue samples associated with asthma in children. Furthermore, we constructed protein-protein interaction (PPI) network for the DEGs and investigated the functional modules of DEGs in NE, peripheral blood mononuclear cells (PBMC) and peripheral blood (PB) samples. Gene Ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed. In addition, gene co-expression network was constructed to identify the critical DEGs in asthmatic children. Our study might provide novel diagnostic biomarkers and therapeutic target molecules in progression of asthma in children.

Materials and methods
=====================

### Data source

The four microarray datasets associated with asthma in children \[access nos. GSE65204 ([@b8-mmr-18-02-2153]), GSE40732 ([@b9-mmr-18-02-2153]), GSE40888 ([@b10-mmr-18-02-2153]), and GSE35571 ([@b11-mmr-18-02-2153])\] were downloaded from National Center of Biotechnology Information (NCBI) GEO database. GSE65204 dataset was sequenced on the platform of GPL14550 Agilent-028004 SurePrint G3 Human GE 8× 60K Microarray ([www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL14550](www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL14550)), including NE tissue samples from 36 asthmatic and 33 non-asthmatic children ([Table I](#tI-mmr-18-02-2153){ref-type="table"}). GSE40732 dataset included PBMCs from 97 atopic asthmatic and 97 nonatopic nonasthmatic children, which was sequenced on platform of GPL16025 NimbleGen Homo sapiens Expression Array \[(100718_HG18_opt_expr) [www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL16025](www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL16025)\]. GSE40888 dataset was sequenced on the platform of GPL6244 (HuGene-1_0-st) Affymetrix Human Gene 1.0 ST Array, including PBMCs samples from 41 asthmatic and 24 non-asthmatic children. GSE35571 dataset contained PB samples from 60 asthmatic and 64 non-asthmatic children based on the platform of GPL570 (HG-U133_Plus_2) Affymetrix Human Genome U133 Plus 2.0 Array.

### DEGs screening

The DEGs between disease groups and control groups were screened by the limma package ([@b12-mmr-18-02-2153]) in R software. The adjusted P-value \<0.05 and \|log2 fold-change (FC)\|\>1 were considered as cut-off criteria.

The microarray data from GSE40732 and GSE40888 datasets were analyzed to identify DEGs in PBMCs samples between asthmatic children and healthy groups. Besides, GSE35571 dataset was used to identify DEGs in PB samples and GSE65204 dataset were used to identify DEGs in NE tissue samples.

### Identification of co-expression modules

To identify the gene co-expression modules related to different tissue samples, we used weighted gene co-expression network analysis (WGCNA) ([@b13-mmr-18-02-2153]) package to further mine the modules. The WGCNA provided topology properties of co-expression network, as well as the correlation of two node genes and relevant other genes. Besides, we changed the connection coefficient into weight coefficient and screened significant co-expression modules that related to different tissue samples using WGCNA analysis.

### PPI network construction

For the identified DEGs, we screened the PPI relationship pairs of DEGs from some common databases. The databases included HPRD ([www.hprd.org/](www.hprd.org/)), BIOGRID ([thebiogrid.org/](thebiogrid.org/)), DIP ([dip.doe-mbi.ucla.edu/dip/Main.cgi](dip.doe-mbi.ucla.edu/dip/Main.cgi)), MINT ([mint.bio.uniroma2.it/mint/Welcome.do](mint.bio.uniroma2.it/mint/Welcome.do)), menthe ([mentha.uniroma2.it/index.php](mentha.uniroma2.it/index.php)), PINA ([cbg.garvan.unsw.edu.au/pina/](cbg.garvan.unsw.edu.au/pina/)), InnateDB ([www.innatedb.com/](www.innatedb.com/)), Instruct ([instruct.yulab.org/index.html](instruct.yulab.org/index.html)). We then obtained the regression coefficient value of each relationship pair in different conditions through linear regression analysis.

To investigate the changes of adjust power under two conditions, we proposed a method to calculate the changes of adjust power associated with screened PPI relationship pairs. The equation is as follows:
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C1*coef*~i~ and C2*coef*~i~ represent regression coefficient value of each relationship pairs in condition 1 and condition 2, respectively; C1*sd*~i~ and C2*csd*~i~ represent standard deviation (SD) values responding to regression coefficient in condition 1 and condition 2, respectively; M represents compensation coefficient; If a relationship pair is only presented in the condition of disease, then its regression coefficients and SD value would be zero in other conditions; d*DRl* ranging from positive to negative value represents that the regulative relations are increased or decreased from condition 1 to 2. The higher the absolute values of d*DRl*, the greater change of adjust power.

In our study, we mainly compared the gene relationships in three types of tissues: NE-Normal (from normal to NE), PB-Normal (from normal to PB) and PBMC-Normal (from normal to PBMC). After calculating d*DRl* values of the whole relationships, we constructed the weighted correlation network. In the network, the d*DRl* values represented edge weight. The higher the absolute values of d*DRl*, the greater significance of relationship pairs. Besides, we performed the KEGG pathway and GO analyses to identify the enrichment functions of DEGs in the network.

### Identification of specific genes

In the weighted correlation network, the dDRl values were used to evaluate the adjusted power of DEGs. For the specific gene g, we calculated its adjusted power through the following formula:
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g represents the specific genes; k represents the number of relationships corresponding with the specific gene; the dDRl can be displayed as dDRl~i~ (i=1, 2, . . ., k). The higher the dDRg values, the greater effect of the specific genes on the network. Finally, we exacted top 10 genes according to the d*DRg* value.

Results
=======

### Identification of DEGs

We identified many DEGs from different tissue samples, including 1,662 DEGs from NE tissue samples, 572 DEGs from PB samples, 146 DEGs from PBMC samples. Furthermore, the genes related to asthma were downloaded from DisGeNET database and the number of genes in three types of tissue was counted, respectively. A total of 169 DEGs related to asthma were screened from NE tissue, 38 DEGs were screened from PB and 14 DEGs were screened from PBMC ([Fig. 1A](#f1-mmr-18-02-2153){ref-type="fig"}).

The Venn diagram was used to visualize the DEGs screened from differential tissues ([Fig. 1B](#f1-mmr-18-02-2153){ref-type="fig"}). Among these genes, colony stimulating factor 3 (*CSF3*) and arachidonate 15-lipoxygenase (*ALOX15*) were significantly differentially expressed in all three types of tissue.

### PPI network analysis

The PPI relationship pairs associated with DEGs were extracted from common databases and the PPI network was constructed. To further explore the DEGs related to PBMC tissue, we take the union set of DEGs in two databases (GSE40732 and GSE40888) to construct the PPI network. In the PPI network, a total of 13496 nodes and 71275 relationship pairs were identified ([Fig. 2A](#f2-mmr-18-02-2153){ref-type="fig"}). F-box only protein 6 (FBXO6) and histone deacetylase 1 (HDAC1) were hub genes and played an important role in the process of asthma. Additionally, we performed the topological centrality analysis of the network. The results showed that there were significance differences between the DEGs in NE and PB samples according to the degree, topological coefficient, and closeness centrality analyses. The values of degree in NE tissue were higher than that in PBMC tissue. The values of degree and closeness centrality in PBMC tissue were higher than that in PB tissue ([Fig. 2C](#f2-mmr-18-02-2153){ref-type="fig"}).

The DEGs related to asthma were downloaded from DisGeNET databases (<http://www.disgenet.org/web/DisGeNET/menu/home;jsessionid=mjbtjh4yncdzuqjlnk3rnvbn>) and a total of 1,403 DEGs were screened, including 104 DEGs associated with asthma in children. We integrated the PPI relationship pairs and constructed the PPI network related to asthma, including 11,960 nodes and 61,164 relationship pairs ([Fig. 2B](#f2-mmr-18-02-2153){ref-type="fig"}). Based on the topology properties analysis (including degree, topological coefficient, closeness centrality and betweenness centrality), we found that there was no significant difference between childhood asthma DEGs and other asthma DEGs ([Fig. 2D](#f2-mmr-18-02-2153){ref-type="fig"}).

### Gene co-expression network analysis

The cuttee Static Color function in the WGCNA package was used to mine the functional modules associated with different tissues. The parameters were set as follows: The X-axis represents gene degrees k, Y-axis represents the ratio of genes p (k) ([Fig. 3A](#f3-mmr-18-02-2153){ref-type="fig"}). Hierarchical cluster diagrams were used to visualize the functional modules associated with different tissues ([Fig. 3B](#f3-mmr-18-02-2153){ref-type="fig"}). A total of 100 genes were selected randomly from network modules and the correlation between these genes were further investigated ([Fig. 3C](#f3-mmr-18-02-2153){ref-type="fig"}).

We analyzed the P-values of each DEG in the disease groups and normal tissues. A higher degree indicated that the DEG had greater connection with other genes and might play an important role in the progression of asthma. K represents the degree of each DEG in the modules. P-values represent the significance of each DEG. The correlation between K values and -log10 (p) was calculated. According to the GO and pathway analysis, we obtained the functional modules related to different tissues. [Fig. 3D](#f3-mmr-18-02-2153){ref-type="fig"} showed functional modules of PB tissue, and functional modules of other tissues were also obtained with the same method (data not shown).

Two functional modules in the color of brown and yellow were screened significantly associated with PB tissue; modules of black and green were significantly related to NE tissue; functional modules in the color of green and red were significantly associated with PBMC tissue.

The GO biological process (BP) enrichment analysis was performed to identify the function of DEGs associated with different tissue in asthmatic children ([Fig. 4](#f4-mmr-18-02-2153){ref-type="fig"}). The GO functional analysis results showed that the DEGs related to PB tissue were mainly enriched in the processes of acid secretion, sensory organ development and negative regulation of cell development, etc; the DEGs related to NE tissue were mainly involved in the processes of positive regulation of cell motility, and positive regulation of cellular component movement; the DEGs in PBMC tissue were mainly enriched in the processes of positive regulation of apoptotic process, and organ induction.

### Construction of regulatory network

We constructed the regulatory network related to DEGs in different tissues ([Fig. 5](#f5-mmr-18-02-2153){ref-type="fig"}). As for the PBMC tissue, we took the interaction of DEGs in two databases to perform WGCNA analysis and the gene expression profile of GSE40732 dataset were used to analysis the adjust power.

The results showed that *FBXO6* was a hub gene in the regulatory network associated with PB tissue, which included 3,670 nodes and 5,330 relationship pairs ([Fig. 5A](#f5-mmr-18-02-2153){ref-type="fig"}). *HDAC1* and cullin-7 (*CUL7*) were hub genes in the regulatory network of PBMC tissue, which included 6,803 nodes and 18,220 relationship pairs ([Fig. 5B](#f5-mmr-18-02-2153){ref-type="fig"}). Additionally, the regulatory network associated with NE tissue included 6,276 nodes and 18,209 relationship pairs, and amyloid β precursor protein (*APP*) was a hub gene ([Fig. 5C](#f5-mmr-18-02-2153){ref-type="fig"}).

### GO and KEGG pathway analyses of DEGs in regulatory network

The pathway analysis results showed that the DEGs in the PB tissue were mainly enriched in MAPK signaling pathway, PI3K-Akt signaling pathway and neurotrophin signaling pathway, etc. ([Fig. 6A](#f6-mmr-18-02-2153){ref-type="fig"}). As for the DEGs in the PBMC tissue, the enriched pathways included neurotrophin signaling pathway, and insulin signaling pathway, etc. ([Fig. 6B](#f6-mmr-18-02-2153){ref-type="fig"}). The DEGs in the NE tissue were significantly enriched in ubiquitin mediated proteolysis, cell cycle and neurotrophin signaling pathway ([Fig. 6C](#f6-mmr-18-02-2153){ref-type="fig"}).

Moreover, the GO BP terms enriched by DEGs in PB tissue were mainly associated with cellular response to organic cyclic compound ([Fig. 7A](#f7-mmr-18-02-2153){ref-type="fig"}). As for the DEGs in PBMC together with DEGs in NE tissue samples, the GO BP terms were related to cell cycle phase transition ([Fig. 7B and C](#f7-mmr-18-02-2153){ref-type="fig"}).

### Specific DEGs in the regulatory network

The DEGs in the regulatory network were sequenced by dDRg values and top 20 DEGs were selected ([Table II](#tII-mmr-18-02-2153){ref-type="table"}). The results showed that proliferating cell nuclear antigen (PCNA), integrin α-4 (ITGA4), catenin α-1 (CTNNA1), nuclear factor-κB1 (NF-κB1) and mechanistic target of rapamycin (MTOR) were specific DEGs that related to asthma. Besides, these DEGs were also identified in DisGetNET database associated with asthma. Our results indicated that PCNA, ITGA4, CTNNA1, NF-κB1 and MTOR might be the potential genes related to asthma in children.

Discussion
==========

In the current study, we identified many DEGs from three types of tissue samples, including 1,662 DEGs from NE tissue samples, 572 DEGs from PB samples, and 146 DEGs from PBMC samples. In PPI network, *FBXO6, HDAC1* and *APP* were hub genes and might play an important role in the process of asthma. In addition, *PCNA, ITGA4, CTNNA1, NF-*κ*B1* and *MTOR* might be critical DEGs related to asthma in children.

*FBXO6* encodes a member of the F-box protein family, which constitutes the subunit of ubiquitin protein ligase complex called SKP1-cullin-F-box (*SCFs*) ([@b14-mmr-18-02-2153]). Overexpression of F-box protein *FBXL19* can abrogate the inflammatory effects of *IL-33* and lessen the severity of pulmonary inflammation in mouse models of pneumonia ([@b15-mmr-18-02-2153]). However, the role of *FBXO6* in asthma has not been reported. In our study, we found that *FBXO6* were hub gene in the PPI network. Together with previous findings, we proposed that *FBXO6* might relate to the inflammation in asthma.

*HDAC1* is a member of *HDAC* family and highly expressed in inflammation-related diseases, such as arthritis ([@b16-mmr-18-02-2153]). Deletion of *HDAC1* increased allergic airway inflammation and promoted Th2 cytokine production in asthma mice, while asthmatic mice treated with herbal extract can resulted in significant anti-inflammatory and anti-allergic activity by increasing expression level of alveolar macrophages *HDAC1* ([@b17-mmr-18-02-2153]). Recent study showed that a polymorphism in the *HDAC1* gene is associated with the response to corticosteroids in asthmatics ([@b18-mmr-18-02-2153]). Our study revealed that *HDAC1* was a hub gene in the PPI network and might play an important role in the process of asthma, which was consisting with previous studies. *PCNA* served as a factor to coordinate DNA replication and epigenetic inheritance, such as DNA methylation ([@b19-mmr-18-02-2153]). A study showed that *PCNA* interacted with *HDAC1* in human cells *in vitro* can co-localize in the cell nucleus, and finally led to integration of DNA replication ([@b20-mmr-18-02-2153]). DNA methylation changes in PB were associated with childhood allergic asthma ([@b9-mmr-18-02-2153]). These finding indicated that *PCNA* interacted with *HDAC1* might involve in DNA methylation of asthma in children. In addition, a previous study showed that *PCNA* expression was associated with the epithelium thickness in corticosteroid-dependent asthma ([@b21-mmr-18-02-2153]). The cell proliferation related molecule *PCNA* and cell activation related molecule *NF-*κ*B* were both highly expressed in corticosteroid-dependent asthmatic subjects ([@b21-mmr-18-02-2153]), revealing the potential role in the treatment and disease epithelium repair.

*ITGA4* is also named as *CD49d*. A study reported that up-regulation of lysophosphatidic acid receptor 1 and down-regulation of *ITGA4* can increase the number of monocytes in the PB and finally impact on immune function ([@b22-mmr-18-02-2153]). However, the relationships between *ITGA4* and asthma disease were unclear. The PPI network analysis in our study revealed that *ITGA4* might be a major factor related to asthma in children. *CTNNA1* is also known as αE-catenin, and it plays a major role in epithelial tissue, both at adherent junctions and in signaling pathways ([@b23-mmr-18-02-2153]). Epithelial damage from airway inflammation during asthma may result in immune response to self-antigens, including α*E-catenin* and epidermal group factor receptor (*EGFR*); and finally contributes to the pathogenesis of asthma ([@b24-mmr-18-02-2153]). Moreover, a replication study in a Caucasian worker population revealed that α-catenin gene variants were also associated with diisocyanate asthma ([@b25-mmr-18-02-2153]). These results suggested that *CTNNA1* might be critical gene that regulated the progressive of asthma in children.

*MTOR* is a serine/threonine kinase that is evolutionary conserved and can regulate lymphocyte cellular immunity by activating cytokine secreted from inflammatory cells ([@b26-mmr-18-02-2153]). *MTORC2* regulated the differentiation of naive CD4+ T cells into Th9 cells, and *mTORC2* deficiency in T cells could result in less severe inflammation in the murine allergic airway inflammation model ([@b27-mmr-18-02-2153]). Zhang *et al* ([@b28-mmr-18-02-2153]) revealed that increased serum *mTOR* pathway activation can lead to elevated levels of Th17 cells and IL-4, following decreased Treg cells and IFN-γ. Our study demonstrated a clear relationship between *MTOR* in the PBMC of childhood patients with allergic asthma. These findings strongly suggested a necessary for *mTOR* pathway activation in asthma process. In addition, *NF-*κ*B1* is reported as a transcription factor that is activated by multiple intra-cellular and extra-cellular stimuli such as cytokines, oxidant-free radicals, and bacterial or viral products ([@b29-mmr-18-02-2153]). Activated *NF-*κ*B* can stimulate the expression of genes involved in many biological or pathological processes, including acute lung injury/acute respiratory distress syndrome and asthma. Recent study showed that the over-expression of *PI3K* and *NF-*κ*B* in childhood asthma were negatively correlated with pulmonary functions, which indicated that *PI3K* and *NF-*κ*B* might involve in the development of bronchial asthma in children ([@b30-mmr-18-02-2153]). Inhibition of the *NF-*κ*B* signaling pathway can improve airway inflammation in an ovalbumin-induced rat model ([@b31-mmr-18-02-2153]). In our study, we also found that the *NF-*κ*B1* and *mTOR* were hub genes related to asthma in children. Considering the previous studies, we suggested that *NF-*κ*B1* interacted with *mTOR* might play an important role in the progression of asthma in children, such as inflammation in asthma. Additionally, a study of asthmatic mouse model indicated that mTOR is activated during asthma onset and inhibited during asthma remission, and blocking the mTOR pathway in asthmatic mice restores the Th17/Treg and Th1/Th2 cytokines balances ([@b28-mmr-18-02-2153]). These findings strongly documented a critical role of mTOR pathway activation in asthma onset, revealing potential targets for asthma treatments.

Using the network analysis, we also identified *APP* hitherto not associated with asthma as important hub gene in regulatory network associated with NE tissue. *APP* gene encoding the amyloid beta precursor protein is known as a major player in Alzheimer\'s disease (AD) that have immune and inflammatory components ([@b32-mmr-18-02-2153]). Recent studies also suggested a link between *APP* and asthma genes ([@b32-mmr-18-02-2153],[@b33-mmr-18-02-2153]). It is revealed that *APP* was potentially associated with airway hyperresponsiveness through the interaction with a disintegrin and metalloproteinase (*ADAM33*) ([@b33-mmr-18-02-2153]). *ADAM33* is an asthma susceptibility gene with catalytic properties, functioned as a negative regulator of *APP* ([@b34-mmr-18-02-2153]). In our module, *APP* was found potentially interacted with other asthma genes, it is speculated that these possible connections can provide new insights for exploring the functional role and relationships of these genes in asthma, as well as in AD.

In conclusion, our findings suggest that genes are differentially expressed in the three type tissue samples of asthmatic children, including NE, PB and PBMC samples. Among these DEGs, *FBXO6, HDAC1* and *APP* interact with *PCNA, ITGA4, CTNNA1, NF-*κ*B1* and *mTOR* might be critical DEGs related to asthma in children.
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![DEGs in three types of tissues associated with asthmatic children and the Venn diagrams. (A) The DEGs in three types of tissues associated with asthmatic children. (B) Venn diagrams presenting the number of DEGs in the different tissues of asthmatic children. DEGs, differentially expressed genes; PB, peripheral blood; PBMC, peripheral blood mononuclear cells; NE, nasal-epithelium; CSF3, colony stimulating factor 3; ALOX15, arachidonate 15-lipoxygenase; SLAMF7, SLAM family member 7.](MMR-18-02-2153-g02){#f1-mmr-18-02-2153}

![PPI network construction and analysis. (A) The PPI network of DEGs. (B) The PPI network of DEGs in the different tissues of asthmatic patients. (C) The topological property comparison of the DEGs between different tissues, including degree, topological coefficient, closeness centrality and betweenness centrality. (D) The topological property comparison between the DEGs of childhood asthmatic patients and non-childhood asthmatic patients. \*P\<0.05, as indicated. PPI, protein-protein interaction; DEGs, differentially expressed genes; NS, not significant.](MMR-18-02-2153-g03){#f2-mmr-18-02-2153}

![Gene co-expression modules analysis of GSE35571. (A) Soft threshold setting in the co-expression network. The x-axis represents gene degrees k, and the y-axis represents the ratio of genes p (k). (B) Hierarchical clustering heatmap of DEGs in co-expression network. (C) Hierarchical clustering heatmap showed the inner correlation between these function modules. (D) The GO enrichment analysis of DEGs in modules. The x-axis represents DEGs of modules and the y-axis represents the significance of GO analysis. DEGs, differentially expressed genes; GO, Gene Ontology.](MMR-18-02-2153-g04){#f3-mmr-18-02-2153}

![Gene Ontology Biological Process analysis of differentially expressed genes in different databases.](MMR-18-02-2153-g05){#f4-mmr-18-02-2153}

![DEGs in the regulatory network associated with different types of tissues. (A) The DEGs in the regulatory network associated with PB. (B) The DEGs in the regulatory network associated with PBMC. (C) The DEGs in the regulatory network associated with NE tissue. DEGs, differentially expressed genes; PB, peripheral blood; PBMC, peripheral blood mononuclear cells; NE, nasal-epithelium.](MMR-18-02-2153-g06){#f5-mmr-18-02-2153}

![Kyoto Encyclopedia of Genes and Genomes pathway analysis for the DEGs in the regulatory network. (A) Pathway analysis for the DEGs in the network associated with PB. (B) Pathway analysis for the DEGs in the network associated with PBMC. (C) Pathway analysis for the DEGs in the network related to NE tissue. DEGs, differentially expressed genes; PB, peripheral blood; PBMC, peripheral blood mononuclear cells; NE, nasal-epithelium.](MMR-18-02-2153-g07){#f6-mmr-18-02-2153}

###### 

GO BP analysis for the DEGs in the regulatory network. (A) GO BP analysis for the DEGs in the regulatory network associated with PB. (B) GO BP analysis for the DEGs in the regulatory network associated with PBMC. (C) GO BP analysis for the DEGs in the regulatory network associated with NE tissue. GO, Gene Ontology; BP, biological process; DEGs, differentially expressed genes; PB, peripheral blood; PBMC, peripheral blood mononuclear cells; NE, nasal-epithelium.
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###### 

Microarray databases associated with asthmatic children, including GSE65204, GSE40732, GSE40888 and GSE35571.

  Accession   Platform   Tissue                               Asthmatic samples (n)   Non-asthmatic samples (n)
  ----------- ---------- ------------------------------------ ----------------------- ---------------------------
  GSE65204    GPL14550   Nasal-epithelium                     36                      33
  GSE40732    GPL16025   Peripheral blood mononuclear cells   97                      97
  GSE40888    GPL6244    Peripheral blood mononuclear cells   41                      24
  GSE35571    GPL570     Peripheral blood                     60                      64

###### 

Top 20 nodes in the regulatory network associated with the DEGs of asthmatic children.

        NE Samples                                              PB Samples   PBMC samples                                                                                                                                                           
  ----- ------------------------------------------------------- ------------ -------------- -------------------------------------------------------- ---------- -------------- ------------------------------------------------------- ------------ --------------
    1   APP                                                     202.5712     No             FBXO6                                                    42.82477   No             HDAC1^[a](#tfn2-mmr-18-02-2153){ref-type="table-fn"}^   106.7973     Other asthma
    2   SETDB1                                                    78.09696   No             ARIH2                                                    36.51952   No             RPS8                                                      61.2846    No
    3   RPA1                                                      68.47313   No             IFI16                                                    33.23794   No             RPS11                                                     58.52655   No
    4   STK4                                                      66.04559   No             PAFAH1B2                                                 30.54515   No             RPS4X                                                     39.92426   No
    5   NEDD4                                                     61.91617   No             TFG                                                      29.83253   No             TRIM27                                                    39.09394   No
    6   CSNK1A1                                                   57.83066   No             FGFR2                                                    26.67677   No             RPL5                                                      35.9798    No
    7   EDC4                                                      53.42212   No             LGALS8                                                   26.21989   No             CUL7                                                      29.2522    No
    8   CTDP1                                                     49.7963    No             NEK6                                                     24.95025   No             NEDD8                                                     28.72204   No
    9   RPS2                                                      43.28688   No             LYAR                                                     22.42635   No             RPS10                                                     27.68076   No
  10    CALM3                                                     41.95928   No             SPINT2                                                   19.52418   No             RPS25                                                     27.62278   No
  11    RPS7                                                      40.06917   No             GOT1                                                     17.31375   No             TMEM216                                                   27.26486   No
  12    IFI16                                                     39.24005   No             MYO6                                                     17.17874   No             NFKB1^[a](#tfn2-mmr-18-02-2153){ref-type="table-fn"}^     25.80718   Other asthma
  13    MID2                                                      35.10338   No             PELO                                                     16.25726   No             RPL35A                                                    25.62394   No
  14    PCNA^[a](#tfn2-mmr-18-02-2153){ref-type="table-fn"}^      32.54975   Other asthma   PTK6                                                     15.76188   No             PSMD4                                                     25.04536   No
  15    RPL10                                                     30.89499   No             CTNNA1^[a](#tfn2-mmr-18-02-2153){ref-type="table-fn"}^   15.75888   Other asthma   EIF3E                                                     19.85108   No
  16    RPS16                                                     29.85522   No             NTRK2                                                    14.60812   No             MTOR^[a](#tfn2-mmr-18-02-2153){ref-type="table-fn"}^      19.81246   Other asthma
  17    ITGA4^[a](#tfn2-mmr-18-02-2153){ref-type="table-fn"}^     29.2464    Other asthma   LIPH                                                     12.77759   No             DDX24                                                     19.53866   No
  18    MCM7                                                      28.55749   No             CA10                                                     12.35675   No             UBQLN4                                                    19.34685   No
  19    SPTAN1                                                    28.18446   No             NUDT3                                                    11.95574   No             ATXN1                                                     18.88822   No
  20    LZTS2                                                     28.04549   No             SLC9A3R2                                                 11.93033   No             IKBKE                                                     17.33138   No

The dDRg values of DEGs in the regulatory network are presented.

DEGs associated with asthma. DEGs, differentially expressed genes; PB, peripheral blood; dDRg, weighted control values; PBMC, peripheral blood mononuclear cells; NE, nasal-epithelium.
